Last updated on February 2018

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM in Primary Immune Deficiency Subjects Aged 2 to 16

Brief description of study

This study is part of the BIVIGAM post marketing requirement (PMR). It is being conducted in subjects aged 2-16 with primary immune deficiency disorders associated with defects in humoral immunity to generate additional data on these populations, and more specifically safety and pharmacokinetic (PK) assessments.

Clinical Study Identifier: NCT03164967

Find a site near you

Start Over

Ohio Clinical Research Associates

Mayfield Heights, OH United States
  Connect »